CNS |
Central nervous system |
CSF |
Cerebrospinal fluid |
DMF |
Dimethyl fumarate |
DMT |
Disease modifying treatment |
EBV |
Epstein Barr Virus |
EAE |
Experimental autoimmune encephalomyelitis |
FGF |
Fibroblast growth factor |
FGFR |
Fibroblast growth factor receptor |
LINGO-1 |
Leucine rich repeat and immunoglobin-like domain-containing protein 1 |
mTOR |
Mammalian target of rapamycin |
MAPK |
Mitogen-activated protein kinase |
Myrf |
Myelin Regulatory Factor |
ERK |
Extracellular signal-regulated kinases |
MS |
Multiple sclerosis |
MOG |
Myelin oligodendrocyte glycoprotein |
OPCs |
Oligodendrocyte progenitor cells |
PROs |
Patient-reported outcomes |
PLC |
Phospholipase C |
PML |
Progressive multifocal leukoencephalopathy |
PKB/Akt |
Protein kinase B |
RRMS |
Relapsing remitting multiple sclerosis |
SEMA3A |
Semaphorin 3A |
STAT |
Signal transducer and activator of transcription |
S1P |
Sphingosine 1-phosphate |
TGF-β |
Transforming growth factor beta |
VLA-4 |
Very late antigen-4 |